SK129695A3 - Application of concentrates contaning vwf factor as combination therapy at the treatment with antithrombotics and fibrinolytics - Google Patents
Application of concentrates contaning vwf factor as combination therapy at the treatment with antithrombotics and fibrinolytics Download PDFInfo
- Publication number
- SK129695A3 SK129695A3 SK1296-95A SK129695A SK129695A3 SK 129695 A3 SK129695 A3 SK 129695A3 SK 129695 A SK129695 A SK 129695A SK 129695 A3 SK129695 A3 SK 129695A3
- Authority
- SK
- Slovakia
- Prior art keywords
- vwf
- bleeding
- hirudin
- treatment
- factor
- Prior art date
Links
- 230000002785 anti-thrombosis Effects 0.000 title claims abstract description 8
- 239000012141 concentrate Substances 0.000 title description 10
- 230000003480 fibrinolytic effect Effects 0.000 title description 10
- 238000011282 treatment Methods 0.000 title description 9
- 229960004676 antithrombotic agent Drugs 0.000 title description 2
- 238000002648 combination therapy Methods 0.000 title description 2
- 102100036537 von Willebrand factor Human genes 0.000 claims abstract description 62
- 108010047303 von Willebrand Factor Proteins 0.000 claims abstract description 61
- 230000000740 bleeding effect Effects 0.000 claims abstract description 32
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 18
- 239000003527 fibrinolytic agent Substances 0.000 claims abstract description 10
- 239000000729 antidote Substances 0.000 claims abstract description 6
- 239000012634 fragment Substances 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims 1
- 229960001134 von willebrand factor Drugs 0.000 abstract description 57
- 208000032843 Hemorrhage Diseases 0.000 description 31
- 208000034158 bleeding Diseases 0.000 description 30
- 229940006607 hirudin Drugs 0.000 description 19
- 238000001802 infusion Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 229940127219 anticoagulant drug Drugs 0.000 description 10
- 241000282887 Suidae Species 0.000 description 9
- 229960000301 factor viii Drugs 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 8
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 108010054218 Factor VIII Proteins 0.000 description 7
- 102000001690 Factor VIII Human genes 0.000 description 7
- 108010007267 Hirudins Proteins 0.000 description 7
- 102000007625 Hirudins Human genes 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 206010053567 Coagulopathies Diseases 0.000 description 5
- 229940122388 Thrombin inhibitor Drugs 0.000 description 5
- 230000035602 clotting Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 239000003868 thrombin inhibitor Substances 0.000 description 5
- 206010040860 Skin haemorrhages Diseases 0.000 description 4
- 230000010100 anticoagulation Effects 0.000 description 4
- 239000013065 commercial product Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010023197 Streptokinase Proteins 0.000 description 3
- 208000024248 Vascular System injury Diseases 0.000 description 3
- 208000012339 Vascular injury Diseases 0.000 description 3
- 229940075522 antidotes Drugs 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 229960004281 desmopressin Drugs 0.000 description 3
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
- 229960005202 streptokinase Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 2
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- KXNPVXPOPUZYGB-IOVMHBDKSA-N (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]-1-oxopentyl]-4-methyl-2-piperidinecarboxylic acid Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2 KXNPVXPOPUZYGB-IOVMHBDKSA-N 0.000 description 1
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 108010058207 Anistreplase Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010012088 Fibrinogen Receptors Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960002054 acenocoumarol Drugs 0.000 description 1
- VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- 229960003375 aminomethylbenzoic acid Drugs 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000002506 anticoagulant protein Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229940105776 factor viii inhibitor bypassing activity Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960004923 phenprocoumon Drugs 0.000 description 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 108010039231 polyethyleneglycol-hirudin Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 108010033683 von Willebrand factor drug combination factor VIII Proteins 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4437544A DE4437544A1 (de) | 1994-10-20 | 1994-10-20 | Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK129695A3 true SK129695A3 (en) | 1996-10-02 |
Family
ID=6531287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1296-95A SK129695A3 (en) | 1994-10-20 | 1995-10-18 | Application of concentrates contaning vwf factor as combination therapy at the treatment with antithrombotics and fibrinolytics |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5571784A (no) |
| EP (1) | EP0713881A3 (no) |
| JP (1) | JPH08208504A (no) |
| KR (1) | KR960013383A (no) |
| CN (1) | CN1128168A (no) |
| AU (1) | AU708670B2 (no) |
| CA (1) | CA2160975A1 (no) |
| CZ (1) | CZ287878B6 (no) |
| DE (1) | DE4437544A1 (no) |
| FI (1) | FI954964A (no) |
| HR (1) | HRP950525A2 (no) |
| HU (1) | HU219595B (no) |
| IL (1) | IL115652A (no) |
| NO (1) | NO954175L (no) |
| NZ (1) | NZ280274A (no) |
| PL (1) | PL183182B1 (no) |
| SK (1) | SK129695A3 (no) |
| TW (1) | TW398977B (no) |
| UY (1) | UY24063A1 (no) |
| ZA (1) | ZA958838B (no) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5772629A (en) * | 1995-10-23 | 1998-06-30 | Localmed, Inc. | Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels |
| AT405485B (de) * | 1997-05-28 | 1999-08-25 | Immuno Ag | Eine das vwf-propeptid enthaltende pharmazeutische präparation |
| AT409335B (de) * | 1998-11-10 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen |
| US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
| EP1148063A1 (de) * | 2000-04-18 | 2001-10-24 | Octapharma AG | Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung |
| JP2003284570A (ja) | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | フォンビルブラント因子（ｖＷＦ）切断酵素 |
| DE102008032361A1 (de) | 2008-07-10 | 2010-01-21 | Csl Behring Gmbh | Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie |
| US20130040888A1 (en) * | 2010-02-16 | 2013-02-14 | Novo Nordisk A/S | Factor VIII Molecules With Reduced VWF Binding |
| EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| TWI580423B (zh) * | 2013-12-24 | 2017-05-01 | 財團法人工業技術研究院 | 緩解或治療痛風之醫藥組合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198349A (en) * | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| US5200510A (en) * | 1987-06-16 | 1993-04-06 | Zymogenetics, Inc. | Method for purifying factor viii:c, von willebrand factor and complexes thereof |
| US4774323A (en) * | 1987-06-29 | 1988-09-27 | Rorer Pharmaceutical Corporation | Purification of von Willebrand Factor solutions using gel permeation chromatography |
| FR2619314B1 (fr) * | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| GB8823480D0 (en) * | 1988-10-06 | 1988-11-16 | Ciba Geigy Ag | Antidote |
| US5204323B1 (en) | 1988-10-06 | 1995-07-18 | Ciba Geigy Corp | Hirudin antidotal compositions and methods |
| FR2673632A1 (fr) * | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
| DE4115453A1 (de) * | 1991-05-11 | 1992-11-12 | Knoll Ag | Neue wirkstoffkombination |
| US5366869A (en) * | 1991-11-08 | 1994-11-22 | Sheldon Goldstein | Multiple coagulation test device and method |
| DE4203965A1 (de) * | 1992-02-11 | 1993-08-12 | Max Planck Gesellschaft | Antidot fuer hirudin und synthetische thrombininhibitoren |
| ZA942818B (en) * | 1993-04-23 | 1995-01-30 | Bio Technology General Corp | Method of enhancing thrombolysis. |
-
1994
- 1994-10-20 DE DE4437544A patent/DE4437544A1/de not_active Withdrawn
-
1995
- 1995-09-21 EP EP95114846A patent/EP0713881A3/de not_active Withdrawn
- 1995-09-29 TW TW084110150A patent/TW398977B/zh not_active IP Right Cessation
- 1995-10-16 UY UY24063A patent/UY24063A1/es unknown
- 1995-10-18 CN CN95118715A patent/CN1128168A/zh active Pending
- 1995-10-18 IL IL11565295A patent/IL115652A/xx not_active IP Right Cessation
- 1995-10-18 AU AU34304/95A patent/AU708670B2/en not_active Ceased
- 1995-10-18 HR HRP4437544.1A patent/HRP950525A2/hr not_active Application Discontinuation
- 1995-10-18 FI FI954964A patent/FI954964A/fi unknown
- 1995-10-18 SK SK1296-95A patent/SK129695A3/sk unknown
- 1995-10-18 US US08/544,867 patent/US5571784A/en not_active Expired - Fee Related
- 1995-10-18 NZ NZ280274A patent/NZ280274A/en unknown
- 1995-10-18 CZ CZ19952719A patent/CZ287878B6/cs not_active IP Right Cessation
- 1995-10-18 KR KR1019950035874A patent/KR960013383A/ko not_active Application Discontinuation
- 1995-10-19 NO NO954175A patent/NO954175L/no not_active Application Discontinuation
- 1995-10-19 CA CA002160975A patent/CA2160975A1/en not_active Abandoned
- 1995-10-19 JP JP7270785A patent/JPH08208504A/ja active Pending
- 1995-10-19 ZA ZA958838A patent/ZA958838B/xx unknown
- 1995-10-19 PL PL95311031A patent/PL183182B1/pl unknown
- 1995-10-20 HU HU9503031A patent/HU219595B/hu not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU3430495A (en) | 1996-05-02 |
| NZ280274A (en) | 1997-01-29 |
| PL311031A1 (en) | 1996-04-29 |
| CZ287878B6 (cs) | 2001-03-14 |
| NO954175L (no) | 1996-04-22 |
| NO954175D0 (no) | 1995-10-19 |
| UY24063A1 (es) | 1995-10-24 |
| HU9503031D0 (en) | 1995-12-28 |
| IL115652A0 (en) | 1996-01-19 |
| AU708670B2 (en) | 1999-08-12 |
| ZA958838B (en) | 1996-05-13 |
| KR960013383A (ko) | 1996-05-22 |
| CA2160975A1 (en) | 1996-04-21 |
| IL115652A (en) | 2000-08-31 |
| DE4437544A1 (de) | 1996-04-25 |
| EP0713881A3 (de) | 1996-08-21 |
| JPH08208504A (ja) | 1996-08-13 |
| HUT73762A (en) | 1996-09-30 |
| HU219595B (hu) | 2001-05-28 |
| FI954964A0 (fi) | 1995-10-18 |
| EP0713881A2 (de) | 1996-05-29 |
| PL183182B1 (pl) | 2002-06-28 |
| CZ271995A3 (en) | 1996-05-15 |
| CN1128168A (zh) | 1996-08-07 |
| HRP950525A2 (en) | 1997-04-30 |
| FI954964A (fi) | 1996-04-21 |
| US5571784A (en) | 1996-11-05 |
| TW398977B (en) | 2000-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Woodman et al. | Bleeding complications associated with cardiopulmonary bypass | |
| Levy | Pharmacologic preservation of the hemostatic system during cardiac surgery | |
| Franchini | The use of desmopressin as a hemostatic agent: a concise review | |
| Elg et al. | Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor | |
| JP5653916B2 (ja) | 血小板のインヒビターにより誘発される凝固障害を治療するためのフォン・ヴィレブランド因子または第ｖｉｉｉ因子およびフォン・ヴィレブランド因子 | |
| Macik et al. | Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study | |
| CA2684075A1 (en) | Providing hemostasis in anticoagulated blood by using zeolites | |
| JP3859176B2 (ja) | 抗凝血物質に対する解毒剤として用いるのに適した組成物およびそれらの使用 | |
| SK129695A3 (en) | Application of concentrates contaning vwf factor as combination therapy at the treatment with antithrombotics and fibrinolytics | |
| TWI441645B (zh) | 作為新穎之局部用止血劑的活化型因子Ｘ（ＦＸａ）刺激劑 | |
| Casonato et al. | Re-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand's disease | |
| SCHULMAN et al. | The feasibility of using concentrates containing factor IX for continuous infusion | |
| JP3838680B2 (ja) | 抗凝血物質に対する解毒剤として用いるのに適した医薬およびその使用 | |
| Rubin et al. | New RGD analogue inhibits human platelet adhesion and aggregation and eliminates platelet deposition on canine vascular grafts | |
| Chiu et al. | Transfusion-sparing hemostatic agents | |
| JP2001181204A (ja) | 血液凝固異常に基づく疾患の治療・予防用医薬組成物 | |
| Schulman | Haemostatic and replacement therapy in von Willebrand disease | |
| Maslow et al. | Cardiopulmonary bypass-associated coagulopathies and prophylactic therapy | |
| Rivera et al. | von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions | |
| Lesnikoski et al. | Thrombin inhibition in discordant xenograft rejection | |
| Glazer et al. | Pathologic inhibitors: management with factor VIIa | |
| van Ryn et al. | Dabigatran Etexilate: Pharmacology of the New, Oral Direct Thrombin Inhibitor | |
| Levy | New Concepts in the Treatment and Prevention of Bleeding | |
| MUNTEAN | In vitro Effects of combined Administration of Eptifibatide and Anticoagulants on Thrombin induced Platelet Aggregation after high versus low Coagulant Activation of Platelet Rich Plasma |